

REMARKS

I. Amendments

By this amendment, claims 19, 28 and 33 have been amended and claims 17, 25-27 and 34 have been cancelled.

This amendment adds no new matter to the specification, as the amendments to claims 19, 28 and 33 are only to cancel subject matter.

II. Acknowledgement of the Allowable Claims

Applicants hereby acknowledge the Examiner's confirmation of the allowability of claims 1-16 and 18 in view of the March 11, 2003 Information Disclosure Statement.

III. Discussion of the Rejection under 35 U.S.C. Sec. 112, First Paragraph of Claims 17, 19, 25-28, 33 and 34

Claims 17, 19, 25-28, 33 and 34 remain rejected under 35 U.S.C. Sec. 112, first paragraph as allegedly lacking enablement for prodrugs. Applicants respectfully traverse the rejection.

By this amendment, claims 19, 28 and 33 have been amended to delete prodrugs and claims 17, 25-27 and 34 have been cancelled.

Therefore Applicants respectfully request withdrawal of the 35 U.S.C. Sec. 112, first paragraph rejection of claims 17, 19, 25-28, 33 and 34.

IV. Discussion of the Rejection under 35 U.S.C. Sec. 112, First Paragraph of Claims 25-27 and 34

Claims 25-27 and 34 remain rejected under 35 U.S.C. Sec. 112, first paragraph as allegedly lacking enablement for treating diseases other than cranial trauma. Applicants respectfully traverse the rejection.

To advance the prosecution of the case, claims 25-27 and 34 have been cancelled, without prejudice to the filing of future continuing applications.

Therefore Applicants respectfully request withdrawal of the 35 U.S.C. Sec. 112, first paragraph rejection of claims 25-27 and 34.

V. Conclusion

Reconsideration of the claims and allowance is requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: October 22, 2004

Elaine M Ramesh

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants


Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

Certificate of Mailing under 37 CFR 1.10

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date October 22, 2004 .

Express Mail Label No. EV 524906138 US


Printed Name: Gail L. Winokur